EUVIMEDEUVIMED entdecken
Leserbrief

Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Melek Cihanbeylerden iD, João Teixeira iD, Hazal Kayıkçı, Çise Tüccar, Ali Fuat Kalyoncu, Ebru Damadoglu iD, Margarida Gonçalo iD, Gül Karakaya

Allergy · 2025-05 · 80 (5) · 1495-1497

DOI: 10.1111/all.16458 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Allergy, online erschienen am 26.12.2024. Verfasst von Melek Cihanbeylerden und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Pulmonology, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey.
  • Department of Dermatology and Venereology, University Hospital, Coimbra Local Health Unit, Coimbra, Portugal.
  • Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

ORCID-Profile: Melek Cihanbeylerden, João Teixeira, Ebru Damadoglu, Margarida Gonçalo

Zitieren

APA

Cihanbeylerden, M., Teixeira, J., Kayıkçı, H., Tüccar, Ç., Kalyoncu, A. F., Damadoglu, E., Gonçalo, M., & Karakaya, G. (2025). Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria. Allergy, 80(5), 1495-1497. https://doi.org/10.1111/all.16458

Vancouver

Cihanbeylerden M, Teixeira J, Kayıkçı H, Tüccar Ç, Kalyoncu AF, Damadoglu E, et al. Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria. Allergy. 2025;80(5):1495-1497. doi:10.1111/all.16458

BibTeX
@article{Cihanbeylerden2025,
  author = {Cihanbeylerden, Melek and Teixeira, João and Kayıkçı, Hazal and Tüccar, Çise and Kalyoncu, Ali Fuat and Damadoglu, Ebru and Gonçalo, Margarida and Karakaya, Gül},
  title = {Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria},
  journal = {Allergy},
  year = {2025},
  volume = {80},
  number = {5},
  pages = {1495--1497},
  doi = {10.1111/all.16458}
}
Kostenlos starten →